AUA Guidelines: Advanced Prostate Cancer

AUA2026: Contemporary Management of Advanced Prostate Cancer: Guidelines and Beyond CME Available: https://cme.auanet.org/URL/26DC040ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing, genetic counseling as well as somatic testing. 2. Describe appropriate use of treatment-related to specific genetic alterations. 3. Identify appropriate combination therapy with ADT plus novel androgen receptor pathway inhibitors and chemotherapy. Early treatment intensification as well as appropriate de intensification will be discussed in mHSCPC. 4. Describe the treatments for non-metastatic CRPC and oncologic outcomes based on AUA/SUO and NCCN Guidelines. 5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO and NCCN Guidelines. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc

AUA2026: Focus on: Muscle Invasive Bladder Cancer CME Available: https://cme.auanet.org/URL/FOCUS266ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Evaluate limitations in the current MIBC treatment landscape including patient outcomes and gaps in available systemic therapies to identify individuals with limited or no effective treatment options and enhance clinical decision-making. 2. Interpret the mechanisms of action and clinical data supporting antibody-drug conjugates (ADCs) to determine their potential role in addressing unmet therapeutic needs in patients with MIBC who are ineligible for traditional treatment pathways. 3. Incorporate evidence-based perioperative systemic treatment strategies including neoadjuvant and adjuvant approaches into patient care algorithms to improve pathologic response rates and survival outcomes in MIBC. 4. Apply best practices for managing and mitigating adverse events associated with emerging systemic and perioperative therapies to optimize treatment adherence and patient safety in the MIBC setting. 5. Implement strategies for effective communication, multidisciplinary care coordination, and shared decision-making between urologists, medical oncologists, and patients to improve treatment alignment and patient-centered outcomes in MIBC. ACKNOWLEDGEMENTS: Support provided by an independent educational grant from: Pfizer, Inc.

AUA2026: Focus on: ADT in the Modern Era - Balancing Cancer Control and Cardiovascular Safety CME Available: https://cme.auanet.org/URL/FOCUS265ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Integrate cardiovascular (CV) risk assessment into ADT initiation by applying key findings from the REVELUTION-1 trial to identify patients at elevated risk for atherosclerosis and MACE. 2. Compare and apply the CV safety profiles of LHRH agonists versus GnRH receptor antagonists to guide personalized ADT selection in patients with varying CV risk. 3. Implement streamlined monitoring strategies for men on oral ADT, including testosterone levels, lipid and blood pressure evaluation, and surveillance for early CV risk indicators. 4. Collaborate with cardiology and primary care to optimize statin use and coordinate CV risk-reduction strategies for prostate cancer patients receiving ADT. 5. Strengthen shared decision making and adherence by incorporating discussions of oncologic benefit, CV risk, and mitigation strategies into routine oral ADT counseling and follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Pfizer, Inc Sumitomo Pharma America, Inc.

Innovations in the Surgical Management of BPH (2026) CME Available: https://cme.auanet.org/URL/surgical-treatment-bph-2026 LEARNING OBJECTIVES: After participating in this educational series, participants will be able to: 1. Utilize the newly released AUA Guidelines Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice. 2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them. 3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics. 4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: - Olympus Corporation of the Americas - Teleflex Interventional Urology © 2026 AMERICAN UROLOGICAL ASSOCIATION. ALL RIGHTS RESERVED. ATTENTION: You are prohibited from using or uploading content you accessed through this activity into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

AUA Guidelines: Advanced Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Kristen R. Scarpato, MD, MPH To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

AUA Guidelines: Clinically Localized Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: James Eastham, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer

Update Series (2026): Kidney Stones and the Infected Patient Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Mantu Gupta, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging